Abstract Library

#4216 Immunohistochemical analysis for galectin-3 and outcomes in medullary thyroid cancer

Introduction: Galectin-3 (Gal-3) is a beta-galactoside involved in multiple biological and pathological processes including growth and differentiation, cellular adhesion and transformation, and metastatic potential.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Giampietro A, Lugli F, Maratta M,

Keywords: Thyroid, MTC, Galectine3,

#3999 Exploring the biological and clinical heterogeneity of grade 2 pancreatic neuroendocrine tumors: Insights into diagnosis, prognosis, and therapeutic targets

Introduction: Pancreatic neuroendocrine neoplasms (PanNENs) show heterogeneous behavior, mainly related to their grade (G), nevertheless small well-differentiated G1 and G2 lesions are usually approached the same conservative way.

Conference:

Presenting Author:

Authors: Gallo C, Lorenzo Andrea C, Pietro I, Sara M,

Keywords: pancreas, neuroendocrine, survival, grading,

#3719 Outcomes of surgical treatment for small bowel neuroendocrine neoplasms – The first preliminary results of the international study group for small bowel neuroendocrine neoplasm surgery registry

Introduction: Evidence for surgical treatment of small bowel neuroendocrine neoplasms (SB-NEN) often originates from single center studies. This is the first project of international study group for small bowel neuroendocrine neoplasm surgery, aiming to build and an observational registry to facilitate future research projects and randomized clinical trials.

Conference:

Presenting Author: Kaçmaz E

Authors: Kaçmaz E, Addeo P, Hennings J, Makay �, Pasquer A,

Keywords: minimally invasive surgery, laparoscopic surgery, multicenter study, international registry, small bowel NET,

#3632 Medullary thyroid carcinoma and somatostatin analogues, a possible therapeutic choice in asymptomatic and slow radiological progression metastatic recurrent disease after surgery – Case report of a 22-years long term survival patient

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor of the thyroid and accounts for 1%-2% of thyroid cancers in the United States. MTCs present with locoregional metastasis in 50% of patients and distant metastasis in 10%-15% at diagnosis. Treatment options for recurrent or progressive disease according to RECIST 1.1 criteria, are limited. Tyrosine kinase-inhibitors (TKI) are preferred as first-line systemic therapy. Although somatostatin analogues (SSA) may play a role in MTC, limited evidence is available.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Maratta M, Giampietro A, de Marinis L,

Keywords: medullary thyroid carcinoma (MTC), somatostatin analogues, survival,

#3479 Mesenteric fibrosis in SI-NEN is characterized by strong dysregulation of CXCL9, IL6, COMP and COL6A6 genes

Introduction: Small intestine neuroendocrine neoplasms (SI-NENs) are characterized by the development of desmoplastic mesenteric fibrosis (MF) in up to 50 % of cases. This can cause intestinal obstruction and ischemia, which is a significant clinical problem.

Conference:

Presenting Author:

Authors: Graf S, Keber C, Hattesohl A, Denkert C, Di Fazio P,

Keywords: si-nen, si-net, comp, col6a6, cxcl9, il6, mesenteric fibrosis, desmoplasia, desmoplastic reaction, tumor microenvironment, tme, tumor stroma interaction, next generation sequencing, ngs, htg edgeseq, gene expression analysis, rna,